Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapy.
Cervical cancer recurs in ~30% of cases, for which a favorable prognosis is often unattainable. We describe a cervical cancer patient who developed metastatic disease ~5 years after her initial diagnosis. She was subsequently treated with six cycles of paclitaxel (175 mg/m) and carboplatin area under the curve (AUC) 5 chemotherapy every 21 days, and paclitaxel (135 mg/m) maintenance therapy every 21 days; the patient has remained in clinical remission after more than 5 years of follow-up. Chemotherapy has not historically been effective in managing recurrent, persistent, or metastatic cervical cancer. However, our case study involving paclitaxel and carboplatin chemotherapy with maintenance chemotherapy represents one of the longest documented remission rates in association with the management of recurrent cervical cancer.
aGynecologic Oncology Associates bDepartment of Radiology, Hoag Memorial Hospital, Newport Beach cDepartment of Pathology, St. Joseph Hospital, Orange, California, USA.
John P
JP
Micha
Aaron F
AF
Sassoon
Humberto
H
Wong
Bram H
BH
Goldstein
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D060046:Maintenance Chemotherapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D017239:Paclitaxel / Q000008:administration & dosage; D012074:Remission Induction; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D016190:Carboplatin; D017239:Paclitaxel